Pharmacokinetics of the HIV integrase inhibitor S/GSK1349572 co-administered with acid-reducing agents and multivitamins in healthy volunteers

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 7, 2011, Pages 1567-1572

  Patel, Parul ^a   Song, Ivy ^a   Borland, Julie ^a   Patel, Apurva ^a   Lou, Yu ^a   Chen, Shuguang ^a   Wajima, Toshihiro ^b   Peppercorn, Amanda ^a   Min, Sherene S ^a   Piscitelli, Stephen C ^a  

^a GLAXOSMITHKLINE   (United States)

^b SHIONOGI AND CO LTD   (Japan)

Author keywords

Antiretroviral therapy; Drug interaction; Metal cations

Indexed keywords

ALUMINUM MAGNESIUM HYDROXIDE; INTEGRASE INHIBITOR; MULTIVITAMIN; MYLANTA; OMEPRAZOLE; ONE A DAY; PRISOLEC; S GSK 1349572; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INDUCED HEADACHE; DYSPEPSIA; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PHARMACOKINETICS; PLASMA CONCENTRATION-TIME CURVE; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTACIDS; ANTHRACENES; ANTI-HIV AGENTS; FEMALE; HUMAN EXPERIMENTATION; HUMANS; MALE; VITAMINS;

EID: 79958856040     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr139     Document Type: Article

References (17)

1. Markowitz M, Nguyen BY, Gotuzzo E et al. Rapid and durable antiretroviral effect of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007; 46: 125-33.
2. Zolopa AR, Lampiris H, Blick G et al. The HIV integrase inhibitor elvitegravir has potent and durable activity in treatment-experienced patients with active optimized background therapy. In: Abstracts of the Forty-seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2007. Abstract H-714. American Society for Microbiology, Washington, DC, USA.
3. Lalezari J, Sloan L, DeJesus E et al. Potent antiviral activity of S/GSK1349572, a next generation integrase inhibitor (INI), in INI-naïve HIV-1-infected patients. In: Abstracts of the Fifth IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, 2009. Abstract TUAB105. International AIDS Society, Geneva, Switzerland.
4. Arribas J, Lazzarin A, Raffi F et al. Once-daily S/GSK1349572 as part of combination therapy in antiretroviral naive adults: rapid and potent antiviral responses in the interim 16-week analysis from SPRING-1 (ING112276). In: Abstracts of the Eighteenth International AIDS Conference, Vienna, Austria, 2010. Abstract THLBB205. International AIDS Society, Geneva, Switzerland.
5. Underwood M, Johns B, Sato A et al. S/GSK1349572: a next generation integrase inhibitor with activity against integrase inhibitor-resistant clinical isolates from patients experiencing virologic failure while on raltegravir therapy. In: Posters of the Fifth IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, 2009. Poster WEPEA098. International AIDS Society, Geneva, Switzerland.
6. Song I, Chen S, Lou Y et al. Pharmacokinetic (PK) and pharmacodynamic (PD) relationship of S/GSK1349572, a next generation integrase inhibitor (INI), in HIV-1 infected patients. In: Posters of the Fifth IAS Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, South Africa, 2009. Poster WEPEB250. International AIDS Society, Geneva, Switzerland.
7. Min S, Song I, Borland J et al. Pharmacokinetics and safety of S/GSK1349572, a next generation HIV integrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother 2010; 54: 254-8.
8. Ramanathan S, Shen G, Hinkle J et al. Pharmacokinetic evaluation of drug interactions with ritonavir boosted HIV integrase inhibitor GS-9137 (elvitegravir) and acid reducing agents. In: Abstracts of the Eighth International Workshop on Clinical Pharmacology of HIV Therapy, Budapest, Hungary, 2007. Abstract 69. Virology Education, Utrecht, The Netherlands.
9. Kiser JJ, Bumpass JB, Meditz AL et al. Effect of antacids on the pharmacokinetics of raltegravir in human immunodeficiency virus-seronegative volunteers. Antimicrob Agents Chemother 2010; 54: 4999-5003.
10. Blume H, Donath F, Warnke A et al. Pharmacokinetic drug interaction profiles of proton pump inhibitors. Drug Saf 2006; 29: 769-84.
11. Iwamoto M, Wenning LA, Nguyen BY et al. Effects of omeprazole on plasma levels of raltegravir. Clin Infect Dis 2009; 48: 489-92.
12. Agarwala S, Gray K, Wang Y et al. Pharmacokinetic effect of omeprazole on atazanavir co-administered with ritonavir in healthy subjects. In: Posters of the Twelfth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2005. Poster 658. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
13. Agarwala S, Eley T, Villegas C et al. Pharmacokinetic effect of famotidine on atazanavir with and without ritonavir in healthy subjects. In: Abstracts of the Sixth International Workshop on Clinical Pharmacology of HIV Therapy, Quebec, Canada, 2005. Abstract 11. Virology Education, Utrecht, The Netherlands.
14. Klein CE, Chiu Y, Cai Y et al. Effects of acid-reducing agents on the pharmacokinetics of lopinavir/ritonavir and ritonavir-boosted atazanavir. J Clin Pharmacol 2008; 48: 553-62.
15. Cipro [package insert]. Wayne, NJ, USA: Bayer Healthcare Pharmaceuticals, Inc., 2009.
16. Kirchheiner J, Glatt S, Fuhr U et al. Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol 2009; 65: 19-31.
17. Rhame F, Matson M, Wood D et al. Effects of famotidine and omeprazole on raltegravir pharmacokinetics in HIV-infected persons. In: Abstracts of the Twelfth European AIDS Conference, Cologne, Germany, 2009. Abstract PE4.1/1. European AIDS Clinical Society, Paris, France.